Compare Humana Inc (HUM) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Visa Inc — how do they compare? Humana Inc trades at $404.33 (market cap $47.81B), while Visa Inc trades at $357.29 (market cap $685.71B). The key difference: Visa Inc is far larger — about 14.3× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| HUM | V | |
|---|---|---|
Market Cap | $47.81B | $685.71B |
Sector | Health | Financials |
52-Week High | $409.42 | $365.14 |
52-Week Low | $163.67 | $295.52 |
Enterprise Value | $56.85B | $696.30B |
Dividend Yield | 0.89% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Visa (V) trades at $358.50, showing minimal daily movement (-0.02%) with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.31 versus $3.10 expected, and maintains exceptional profitability with 51.68% net income margin. Recent developments include the launch of Intelligent Commerce Connect to facilitate AI-powered commerce and expanded stablecoin partnerships.
Visa presents a compelling long-term investment case with 85% analyst buy ratings and $396.70 consensus price target suggesting 11% upside. The company's dominant payment network position, AI integration initiatives, and strong cash flow generation support continued growth, though investors should monitor competitive threats from fintech disruption and regulatory pressures that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
